The development of vitiligo in patients treated with anti-PD-1 is caused by the activated anti-melanoma immunity that targets both malignant and healthy melanocytes [72,73] and, its occurrence has been associated with an objective response and a prolonged overall survival [12]. This evidence concerns the gene PDCD1 and vitiligo.